Richard Rosenquist Brandell, MD, of Karolinska Institute, Solna, Stockholm, discusses how the management of chronic lymphocytic leukemia (CLL) has changed since the advent of next-generation techniques as well as gene panel assays currently used for CLL prognosis and resistance assesment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).